India Reports 257 Active COVID-19 Cases as of May 24, 2025, Amid JN.1 Variant Watch
India is closely monitoring a slight uptick in COVID-19 cases, with the Union Health Ministry reporting 257 active cases as of May 24, 2025, marking the highest number in the past year. The majority of these cases are concentrated in Kerala (95 cases), Tamil Nadu (66 cases), and Maharashtra (56 cases). Health officials attribute this rise to the highly transmissible JN.1 variant and its sub-lineages, LF.7 and NB.1.8, which are also driving surges in Southeast Asian countries like Singapore and Hong Kong.
Situation Under Control, No Hospitalizations
The Health Ministry, in a recent review meeting chaired by the Director General of Health Services, confirmed that the situation remains stable. Experts from the National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), and other institutions emphasized that nearly all cases are mild, with no hospitalizations required. The Integrated Disease Surveillance Programme (IDSP) continues to track respiratory illnesses nationwide, ensuring early detection of any concerning trends.
“The current COVID-19 situation in India is under control, with all cases being mild,” an official source told PTI. Hospitals have been directed to monitor influenza-like illnesses (ILI) and severe acute respiratory infections (SARI) closely to maintain preparedness.
JN.1 Variant and Regional Breakdown
The JN.1 variant, a descendant of the Omicron BA.2.86 lineage, was first identified in August 2023 and classified as a “variant of interest” by the World Health Organization (WHO) due to its approximately 30 mutations, including the L455S mutation enhancing transmissibility. While there’s no official confirmation that JN.1 is solely responsible for India’s uptick, its sub-lineages, LF.7 and NB.1.8, are under scrutiny. In the past week (May 12–19), Kerala reported 69 new cases, Maharashtra 44, and Tamil Nadu 34. Other states, including Karnataka (8 cases), Gujarat (6 cases), and Delhi (3 cases), have seen sporadic infections.
In Mumbai, 95 cases were reported throughout May, with 16 patients hospitalized, though no severe outcomes have been noted. The Brihanmumbai Municipal Corporation (BMC) stated that no clusters or major outbreaks have been identified, and the situation remains manageable.
Deaths Linked to Comorbidities
Two deaths were reported at Mumbai’s King Edward Memorial (KEM) Hospital involving a 59-year-old cancer patient and a 14-year-old girl with kidney disease. Both tested positive for COVID-19, but doctors confirmed the deaths were due to underlying health conditions, not the virus itself. The BMC has reiterated that COVID-19 is not currently contributing to mortality in these cases.
Health authorities continue to recommend precautions, particularly for vulnerable groups like the elderly and immunocompromised. These include wearing masks in crowded or poorly ventilated areas, regular hand hygiene, staying up-to-date on vaccinations, and isolating if symptomatic. Updated mRNA vaccines (bivalent and monovalent) remain effective against severe outcomes, though their protection against JN.1 infection may be reduced.
India’s Robust Response and Global Context
India’s vaccination campaign, with over 1.7 billion doses administered since January 2021, has built a strong defense against severe COVID-19 outcomes. The country also has an Omicron-specific vaccine, GEMCOVAC-19, available for potential deployment. The Health Ministry’s proactive measures, including enhanced surveillance and hospital readiness, aim to prevent a repeat of the devastating second wave in 2021.
The current uptick aligns with trends in Southeast Asia, where Singapore reported a rise from 11,100 to 14,200 weekly cases in early May, with hospitalizations increasing by nearly 30%. Hong Kong recorded 31 deaths in the first week of May, primarily among the elderly with comorbidities. The WHO attributes these surges to waning immunity rather than increased virulence, a pattern India is monitoring closely.
Public Figures Highlight Ongoing Vigilance
The resurgence has touched public figures, with Bollywood actor Shilpa Shirodkar recently testing positive and urging fans to mask up. Her case serves as a reminder of the virus’s persistence, even as its impact remains mild. Health experts, including Dr. Sandeep Budhiraja of Max Healthcare, note that JN.1’s higher transmissibility is a concern, but there’s no evidence of increased severity.
The Interview Times urges readers to stay vigilant, follow health guidelines, and consult healthcare providers if symptoms like fever, sore throat, or fatigue arise. With robust surveillance and public cooperation, India is well-positioned to manage this mild wave. Stay safe and informed.
Must Read: Top 10 Books on Relationships to Strengthen Your Bonds